AB Science S.A. (0Q77.L)

EUR 0.87

(-6.75%)

Total Liabilities Summary of AB Science S.A.

  • AB Science S.A.'s latest annual total liabilities in 2023 was 46.5 Million EUR , down -21.85% from previous year.
  • AB Science S.A.'s latest quarterly total liabilities in 2024 Q2 was 37.1 Million EUR , down 0.0% from previous quarter.
  • AB Science S.A. reported annual total liabilities of 59.51 Million EUR in 2022, up 33.83% from previous year.
  • AB Science S.A. reported annual total liabilities of 44.46 Million EUR in 2021, down -9.68% from previous year.
  • AB Science S.A. reported quarterly total liabilities of 46.5 Million EUR for 2023 FY, down -21.85% from previous quarter.
  • AB Science S.A. reported quarterly total liabilities of 52.42 Million EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Total Liabilities Chart of AB Science S.A. (2023 - 2009)

Historical Annual Total Liabilities of AB Science S.A. (2023 - 2009)

Year Total Liabilities Total Liabilities Growth
2023 46.5 Million EUR -21.85%
2022 59.51 Million EUR 33.83%
2021 44.46 Million EUR -9.68%
2020 49.23 Million EUR 10.47%
2019 44.56 Million EUR 19.0%
2018 37.45 Million EUR -6.05%
2017 39.86 Million EUR -6.67%
2016 42.71 Million EUR -14.29%
2015 49.83 Million EUR 6.13%
2014 46.95 Million EUR 8.47%
2013 43.29 Million EUR 72.59%
2012 25.08 Million EUR 15.42%
2011 21.73 Million EUR 48.69%
2010 14.61 Million EUR 12.04%
2009 13.04 Million EUR 0.0%

Peer Total Liabilities Comparison of AB Science S.A.

Name Total Liabilities Total Liabilities Difference
Boiron SA 198.7 Million EUR 76.594%
Laboratorios Farmaceuticos Rovi, S.A. 256.39 Million EUR 81.86%
Vetoquinol SA 165.12 Million EUR 71.834%
Valneva SE 341.14 Million EUR 86.367%
Nanobiotix S.A. 95.74 Million EUR 51.423%
PHAXIAM Therapeutics S.A. 25.69 Million EUR -81.0%
Vivoryon Therapeutics N.V. 4.54 Million EUR -922.828%
BioSenic S.A. 32.26 Million EUR -44.148%
ABIVAX Société Anonyme 131.05 Million EUR 64.512%
Formycon AG 387.61 Million EUR 88.001%